Literature DB >> 7629564

Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra).

S Stosić-Grujicić1, N Basara, P Milenković, C A Dinarello.   

Abstract

In the present study we investigated the effects of IL-1 antagonism on the autonomous growth of cells in acute myeloblastic leukemia (AML). To examine the role of pro-IL-1 processing, antisense technology was employed with 16-mer phosphorothioate oligodeoxynucleotide directed against human IL-1 beta converting enzyme (ICR) in 7 randomly selected AML cases. The addition of 10-75 microM of antisense oligonucleotide (but not of control oligonucleotide) significantly inhibited spontaneous proliferation of bone marrow- (BM) and peripheral blood- (PB) derived low density leukemic cells in a dose-dependent way. Similarly, spontaneous as well as induced CFU-AML colony formation was inhibited by human ICE antisense oligonucleotide with sample-to-sample variability. In separate experiments, in order to examine the effects of blockade of endogenously produced IL-1 to IL-1 receptors, the functional activity of human recombinant IL-1 receptor antagonist (IL-1ra) was tested. Continuous exposure to high concentrations of IL-1ra (up to 100 micrograms/ml) produced dose-dependent inhibition of spontaneous proliferation of the BM-derived blast cells from 9 of the 14 patients and of the PB-derived cells from 10 of the 14 patients. However, in some of these patients, the lower IL-1ra doses (down to 100 ng/ml) induced potentiation of spontaneous proliferation, suggesting a novel regulatory pathway for IL-1 receptor engagement. Similar results were obtained on CFU-AML colony formation, showing inhibition at higher IL-1ra doses, but in a few AML cases stimulatory effect at lower IL-1ra doses.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629564     DOI: 10.1179/joc.1995.7.1.67

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  3 in total

1.  Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.

Authors:  Helena Ågerstam; Christine Karlsson; Nils Hansen; Carl Sandén; Maria Askmyr; Sofia von Palffy; Carl Högberg; Marianne Rissler; Mark Wunderlich; Gunnar Juliusson; Johan Richter; Kjell Sjöström; Ravi Bhatia; James C Mulloy; Marcus Järås; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

2.  Sensitizing leukemia stem cells to NF-κB inhibitor treatment in vivo by inactivation of both TNF and IL-1 signaling.

Authors:  Jing Li; Andrew Volk; Jun Zhang; Joseph Cannova; Shaojun Dai; Caiqin Hao; Chenglong Hu; Jiewen Sun; Yan Xu; Wei Wei; Peter Breslin; Sucha Nand; Jianjun Chen; Ameet Kini; Jiang Zhu; Jiwang Zhang
Journal:  Oncotarget       Date:  2017-01-31

3.  Molecular Basis of Selective Cytokine Signaling Inhibition by Antibodies Targeting a Shared Receptor.

Authors:  James K Fields; Kyle Kihn; Gabriel S Birkedal; Erik H Klontz; Kjell Sjöström; Sebastian Günther; Robert Beadenkopf; Göran Forsberg; David Liberg; Greg A Snyder; Daniel Deredge; Eric J Sundberg
Journal:  Front Immunol       Date:  2021-12-24       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.